Precipio, Inc. (PRPO)
USD 5.65
(-0.18%)
USD 5.65
(-0.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -386 Thousand USD | 81.2% |
| 2022 | -2.05 Million USD | 79.95% |
| 2021 | -10.23 Million USD | -778.8% |
| 2020 | -1.16 Million USD | -328.43% |
| 2019 | 510 Thousand USD | -89.2% |
| 2018 | 4.72 Million USD | 49.59% |
| 2017 | 3.15 Million USD | -59.01% |
| 2016 | 7.7 Million USD | 7.72% |
| 2015 | 7.15 Million USD | 24.04% |
| 2014 | 5.76 Million USD | 65.74% |
| 2013 | 3.47 Million USD | 107.83% |
| 2012 | 1.67 Million USD | -76.41% |
| 2011 | 7.09 Million USD | 11.84% |
| 2010 | 6.34 Million USD | 666.52% |
| 2009 | -1.12 Million USD | -282.41% |
| 2008 | 614 Thousand USD | 197.77% |
| 2007 | -628 Thousand USD | -195.59% |
| 2006 | 657 Thousand USD | -18.49% |
| 2005 | 806 Thousand USD | -90.56% |
| 2004 | 8.53 Million USD | 229.07% |
| 2003 | 2.59 Million USD | 131.74% |
| 2002 | -8.17 Million USD | 58.33% |
| 2001 | -19.61 Million USD | 48.65% |
| 2000 | -38.19 Million USD | -320.71% |
| 1999 | 17.3 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 157 Thousand USD | 140.67% |
| 2024 Q2 | -109 Thousand USD | -169.43% |
| 2023 Q3 | -266 Thousand USD | 82.34% |
| 2023 FY | -386 Thousand USD | 81.2% |
| 2023 Q1 | -942 Thousand USD | 54.12% |
| 2023 Q2 | -1.5 Million USD | -59.87% |
| 2023 Q4 | -386 Thousand USD | -45.11% |
| 2022 Q1 | -7.93 Million USD | 22.47% |
| 2022 Q2 | -6.14 Million USD | 22.55% |
| 2022 Q3 | -3.56 Million USD | 42.09% |
| 2022 FY | -2.05 Million USD | 79.95% |
| 2022 Q4 | -2.05 Million USD | 42.33% |
| 2021 FY | -10.23 Million USD | -778.8% |
| 2021 Q1 | -1.56 Million USD | -34.33% |
| 2021 Q2 | -14.84 Million USD | -848.75% |
| 2021 Q3 | -12.44 Million USD | 16.16% |
| 2021 Q4 | -10.23 Million USD | 17.76% |
| 2020 Q4 | -1.16 Million USD | -89.74% |
| 2020 Q3 | -614 Thousand USD | -149.24% |
| 2020 Q2 | 1.24 Million USD | -56.58% |
| 2020 Q1 | 2.87 Million USD | 463.14% |
| 2020 FY | -1.16 Million USD | -328.43% |
| 2019 Q4 | 510 Thousand USD | 335.02% |
| 2019 Q3 | -217 Thousand USD | -1769.23% |
| 2019 FY | 510 Thousand USD | -89.2% |
| 2019 Q1 | 4.11 Million USD | -12.89% |
| 2019 Q2 | 13 Thousand USD | -99.68% |
| 2018 Q3 | 3.48 Million USD | -5.07% |
| 2018 FY | 4.72 Million USD | 49.59% |
| 2018 Q4 | 4.72 Million USD | 35.71% |
| 2018 Q2 | 3.66 Million USD | 6.75% |
| 2018 Q1 | 3.43 Million USD | 8.77% |
| 2017 FY | 3.15 Million USD | -59.01% |
| 2017 Q4 | 3.15 Million USD | 2025.61% |
| 2017 Q3 | -164 Thousand USD | -60.78% |
| 2017 Q2 | -102 Thousand USD | -101.4% |
| 2017 Q1 | 7.3 Million USD | -5.13% |
| 2016 Q4 | 7.7 Million USD | -0.5% |
| 2016 FY | 7.7 Million USD | 7.72% |
| 2016 Q3 | 7.74 Million USD | 4.73% |
| 2016 Q1 | 7.12 Million USD | -0.39% |
| 2016 Q2 | 7.39 Million USD | 3.78% |
| 2015 Q3 | -2.26 Million USD | -142.15% |
| 2015 FY | 7.15 Million USD | 24.04% |
| 2015 Q4 | 7.15 Million USD | 416.18% |
| 2015 Q2 | 5.36 Million USD | 74.85% |
| 2015 Q1 | 3.06 Million USD | -46.77% |
| 2014 Q4 | 5.76 Million USD | 21.88% |
| 2014 FY | 5.76 Million USD | 65.74% |
| 2014 Q3 | 4.73 Million USD | -5.76% |
| 2014 Q2 | 5.02 Million USD | 149.13% |
| 2014 Q1 | 2.01 Million USD | -42.08% |
| 2013 Q3 | 1.45 Million USD | 64.18% |
| 2013 Q1 | -1.66 Million USD | -199.16% |
| 2013 FY | 3.47 Million USD | 107.83% |
| 2013 Q4 | 3.47 Million USD | 139.44% |
| 2013 Q2 | 885 Thousand USD | 153.31% |
| 2012 Q3 | 2.65 Million USD | 153.68% |
| 2012 Q1 | -10.33 Million USD | -245.66% |
| 2012 FY | 1.67 Million USD | -76.41% |
| 2012 Q4 | 1.67 Million USD | -37.02% |
| 2012 Q2 | -4.95 Million USD | 52.09% |
| 2011 FY | 7.09 Million USD | 11.84% |
| 2011 Q4 | 7.09 Million USD | -7.36% |
| 2011 Q3 | 7.66 Million USD | 14.12% |
| 2011 Q2 | 6.71 Million USD | 4.99% |
| 2011 Q1 | 6.39 Million USD | 0.76% |
| 2010 Q3 | -1.05 Million USD | 33.73% |
| 2010 Q4 | 6.34 Million USD | 702.56% |
| 2010 FY | 6.34 Million USD | 666.52% |
| 2010 Q1 | -1.43 Million USD | -28.3% |
| 2010 Q2 | -1.58 Million USD | -10.58% |
| 2009 FY | -1.12 Million USD | -282.41% |
| 2009 Q1 | -469 Thousand USD | -176.38% |
| 2009 Q2 | -466 Thousand USD | 0.64% |
| 2009 Q3 | -516 Thousand USD | -10.73% |
| 2009 Q4 | -1.12 Million USD | -117.05% |
| 2008 Q1 | 550 Thousand USD | 187.58% |
| 2008 FY | 614 Thousand USD | 197.77% |
| 2008 Q3 | 157 Thousand USD | 194.01% |
| 2008 Q4 | 614 Thousand USD | 291.08% |
| 2008 Q2 | -167 Thousand USD | -130.36% |
| 2007 Q1 | -2.24 Million USD | -441.7% |
| 2007 FY | -628 Thousand USD | -195.59% |
| 2007 Q2 | -7.88 Million USD | -251.14% |
| 2007 Q4 | -628 Thousand USD | 29.99% |
| 2007 Q3 | -897 Thousand USD | 88.62% |
| 2006 Q1 | 883 Thousand USD | 9.55% |
| 2006 Q4 | 657 Thousand USD | 133.59% |
| 2006 Q3 | -1.95 Million USD | -158.39% |
| 2006 Q2 | -757 Thousand USD | -185.73% |
| 2006 FY | 657 Thousand USD | -18.49% |
| 2005 Q2 | 6.8 Million USD | 9.2% |
| 2005 Q3 | 7.47 Million USD | 9.93% |
| 2005 Q4 | 806 Thousand USD | -89.22% |
| 2005 Q1 | 6.22 Million USD | -27.05% |
| 2005 FY | 806 Thousand USD | -90.56% |
| 2004 Q2 | 7.44 Million USD | 109.66% |
| 2004 Q4 | 8.53 Million USD | -15.17% |
| 2004 FY | 8.53 Million USD | 229.07% |
| 2004 Q1 | 3.55 Million USD | 36.85% |
| 2004 Q3 | 10.06 Million USD | 35.19% |
| 2003 Q4 | 2.59 Million USD | 41.13% |
| 2003 Q3 | 1.83 Million USD | 1833.96% |
| 2003 FY | 2.59 Million USD | 131.74% |
| 2003 Q1 | -4.89 Million USD | 40.06% |
| 2003 Q2 | -106 Thousand USD | 97.84% |
| 2002 Q2 | -6.35 Million USD | 15.42% |
| 2002 Q3 | -4.23 Million USD | 33.39% |
| 2002 FY | -8.17 Million USD | 58.33% |
| 2002 Q1 | -7.51 Million USD | 61.67% |
| 2002 Q4 | -8.17 Million USD | -92.99% |
| 2001 Q1 | -13.4 Million USD | 64.9% |
| 2001 Q2 | -7.63 Million USD | 43.03% |
| 2001 FY | -19.61 Million USD | 48.65% |
| 2001 Q3 | -9.44 Million USD | -23.72% |
| 2001 Q4 | -19.61 Million USD | -107.61% |
| 2000 Q4 | -38.19 Million USD | 36.8% |
| 2000 Q1 | 17.67 Million USD | 0.0% |
| 2000 Q3 | -60.43 Million USD | -483.92% |
| 2000 FY | -38.19 Million USD | -320.71% |
| 2000 Q2 | 15.74 Million USD | -10.95% |
| 1999 FY | 17.3 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aspira Women's Health Inc. | -331 Thousand USD | -16.616% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 68.944% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 92.895% |
| Standard BioTools Inc. | 46.5 Million USD | 100.83% |
| Inotiv, Inc. | 382.14 Million USD | 100.101% |
| Prenetics Global Limited | -43.33 Million USD | 99.109% |
| Neuronetics, Inc. | 2.79 Million USD | 113.801% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 97.483% |
| Castle Biosciences, Inc. | -83.53 Million USD | 99.538% |
| Psychemedics Corporation | 334 Thousand USD | 215.569% |
| RadNet, Inc. | 1.14 Billion USD | 100.034% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.02% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 100.078% |
| iSpecimen Inc. | -2.14 Million USD | 82.025% |
| OpGen, Inc. | 11.89 Million USD | 103.246% |
| Exagen Inc. | -12.77 Million USD | 96.978% |
| Bionano Genomics, Inc. | 34.88 Million USD | 101.107% |
| CareDx, Inc | -47.97 Million USD | 99.195% |
| Check-Cap Ltd. | -24.75 Million USD | 98.441% |
| Twist Bioscience Corporation | -192.4 Million USD | 99.799% |
| Guardant Health, Inc. | 220.22 Million USD | 100.175% |
| Biodesix, Inc. | 34.3 Million USD | 101.125% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 93.34% |
| Natera, Inc. | -200.1 Million USD | 99.807% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 99.532% |
| Sera Prognostics, Inc. | -2.02 Million USD | 80.91% |
| 23andMe Holding Co. | -141.37 Million USD | 99.727% |
| OPKO Health, Inc. | 230.68 Million USD | 100.167% |
| Personalis, Inc. | -8.02 Million USD | 95.188% |
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 99.022% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 93.473% |
| T2 Biosystems, Inc. | 33.8 Million USD | 101.142% |
| Neogen Corporation | 735.62 Million USD | 100.052% |
| Myriad Genetics, Inc. | 88.1 Million USD | 100.438% |
| ICON Public Limited Company | 3.56 Billion USD | 100.011% |
| NeoGenomics, Inc. | 269.19 Million USD | 100.143% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 97.483% |
| MDxHealth SA | 18.88 Million USD | 102.044% |
| Prenetics Global Limited | -43.33 Million USD | 99.109% |
| Illumina, Inc. | 1.21 Billion USD | 100.032% |
| DarioHealth Corp. | -7.54 Million USD | 94.886% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 84.177% |
| Medpace Holdings, Inc. | -103.32 Million USD | 99.626% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 210.331% |
| Trinity Biotech plc | 63.73 Million USD | 100.606% |
| Sotera Health Company | 2.02 Billion USD | 100.019% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 68.944% |